The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Open accessAbstract
Purpose: Hepatitis B virus (HBV) infection is an important etiology for hepatocellular carcinoma (HCC). We aim to develop a simple clinical score in predicting the risk of HCC among HBV carriers. Patients and Methods: We first evaluated 1,005 patients and found that the following five factors independently predicted HCC development: age, albumin, bilirubin, HBV DNA, and cirrhosis. These variables were used to construct a prediction score ranging from 0 to 44.5. The score was validated in another prospective cohort of 424 patients. Results: During a median follow-up of 10 years, 105 patients (10.%) in the training cohort and 45 patients (10.6%) in the validation cohort developed HCC. Cutoff values of 5 and 20 best discriminated HCC risk. By applying the cutoff value of 5, the score excluded future HCC development with high accuracy (negative predictive value = 97.8% and 97.3% in the training and validation cohorts, respectively). In the validation cohort, the 5-year HCC-free survival rates were 98.3%, 90.5%, and 78.9% in the low-, medium-, and high-risk groups, respectively. The hazard ratios for HCC in the medium- and high-risk groups were 12.8 and 14.6, respectively. Conclusion: A simple prediction score constructed from routine clinical and laboratory parameters is accurate in predicting HCC development in HBV carriers. Future prospective validation is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Self-citationHepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,222
Yuen, M.-F., Tanaka, Y., Fong, D. Y.-T., Fung, J., Wong, D. K.-H., Yuen, J. C.-H., But, D. Y.-K., Chan, A. O.-O., Wong, B. C.-Y., Mizokami, M., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.023 · Cited by 584
Self-citationAssociations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Yeh, S.-H., Chen, P.-J., Iloeje, U. H., Jen, C.-L., Su, J., Wang, L.-Y., Lu, S.-N., You, S.-L., Chen, D.-S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn243 · Cited by 580
Hepatitis B e antigen-negative chronic hepatitis B
Hadziyannis, S. J., & Vassilopoulos, D. (2001) · Hepatology · doi:10.1053/jhep.2001.27834 · Cited by 554
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
SUNG, J. J. Y., TSOI, K. K. F., WONG, V. W. S., LI, K. C. T., & CHAN, H. L. Y. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03816.x · Cited by 370
Self-citationHepatitis B virus DNA levels and outcomes in chronic hepatitis B # †
Chen, C.-J., Yang, H.-I., & Iloeje, U. H. (2009) · Hepatology · doi:10.1002/hep.22884 · Cited by 346
Cited by
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citation(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Epidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Metadata
- Authors
- Wong, V. W.-S., Chan, S. L., Mo, F., Chan, T.-C., Loong, H. H.-F., Wong, G. L.-H., Lui, Y. Y.-N., Chan, A. T.-C., Sung, J. J.-Y., Yeo, W., Chan, H. L.-Y., & Mok, T. S.-K.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-01
- Volume
- 28
- Issue
- 10
- Pages
- 1660-1665
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162566260
- Cited by
- 502
- References
- 23
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. https://app.cochat.ai/papers/10.1200/jco.2009.26.2675
- The paper
- Wong, V. W.-S., Chan, S. L., Mo, F., Chan, T.-C., Loong, H. H.-F., Wong, G. L.-H., Lui, Y. Y.-N., Chan, A. T.-C., Sung, J. J.-Y., Yeo, W., Chan, H. L.-Y., & Mok, T. S.-K. (2010). Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.26.2675
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.